Somewhat Positive Media Coverage Somewhat Unlikely to Impact TESARO (TSRO) Share Price

Media stories about TESARO (NASDAQ:TSRO) have been trending somewhat positive this week, according to Accern Sentiment. Accern identifies positive and negative news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. TESARO earned a media sentiment score of 0.06 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 48.7027281002672 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Here are some of the news stories that may have effected Accern Sentiment’s analysis:

Shares of TESARO (NASDAQ:TSRO) opened at 111.85 on Friday. The company’s market capitalization is $6.06 billion. The stock has a 50 day moving average price of $130.46 and a 200-day moving average price of $149.15. TESARO has a 12 month low of $83.26 and a 12 month high of $192.94.

TESARO (NASDAQ:TSRO) last issued its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($2.82) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($2.52) by $0.30. The business had revenue of $29.50 million for the quarter, compared to analysts’ expectations of $18.61 million. TESARO had a negative net margin of 1,301.19% and a negative return on equity of 104.00%. The business’s quarterly revenue was down 17.6% compared to the same quarter last year. During the same period in the previous year, the business earned ($1.28) earnings per share. Analysts forecast that TESARO will post ($8.45) EPS for the current year.

Several analysts have weighed in on TSRO shares. Oppenheimer Holdings, Inc. started coverage on TESARO in a research report on Thursday, May 25th. They set an “outperform” rating and a $183.00 price objective on the stock. Cann reaffirmed an “outperform” rating on shares of TESARO in a research report on Wednesday, May 24th. Credit Suisse Group set a $198.00 price objective on TESARO and gave the company a “buy” rating in a research report on Monday, June 5th. Wedbush raised TESARO to an “outperform” rating and set a $168.00 price objective on the stock in a research report on Monday, June 5th. Finally, FBR & Co cut their price objective on TESARO from $200.00 to $195.00 and set a “mkt perform” rating on the stock in a research report on Monday, June 5th. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $176.35.

TRADEMARK VIOLATION WARNING: This article was posted by Stock Observer and is the sole property of of Stock Observer. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.thestockobserver.com/2017/08/12/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-tesaro-tsro-share-price.html.

In related news, VP Edward C. English sold 8,500 shares of TESARO stock in a transaction that occurred on Tuesday, June 6th. The shares were sold at an average price of $138.65, for a total transaction of $1,178,525.00. Following the transaction, the vice president now directly owns 5,396 shares of the company’s stock, valued at $748,155.40. The sale was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 40.50% of the company’s stock.

About TESARO

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

Insider Buying and Selling by Quarter for TESARO (NASDAQ:TSRO)

Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply